2-Acetylaminofluorene (2-AAF)

2-AAF was synthesized in the early 1940s by Wilson and Dolber of E.I. du Pont de Nemours as a potential insecticide compound [1]. Before it could be commercialized, its extraordinary carcinogenicity in rats was discovered — it induced tumors in the liver, bladder, breast, ear duct, and small intestine, producing one of the broadest organ-specific carcinogenicity profiles ever observed from a single compound [2]. This multi-organ carcinogenicity made 2-AAF an invaluable research tool for elucidating how carcinogens are metabolically activated and how different tissues respond differently to the same chemical [1]. James and Elizabeth Miller's pioneering work with 2-AAF in the 1940s-60s established the fundamental principles of chemical carcinogen metabolism, showing that N-hydroxylation was the critical activation step — foundational work for which they received numerous honors [2].

2-AAF was never commercially produced or used as a pesticide — its only use is as a research compound in carcinogenesis and metabolism studies [1]. Research laboratory workers handling 2-AAF are the exclusively exposed population [2]. The general public has no exposure pathway [1].

2-AAF is activated by N-hydroxylation (forming N-hydroxy-2-AAF) and subsequent O-sulfonation or O-acetylation to form reactive nitrenium ions that form bulky C8-guanine DNA adducts [1]. These C8-dG adducts are repaired by nucleotide excision repair (NER) — and 2-AAF has been instrumental in characterizing NER pathways in human cells [2]. IARC classifies it as Group 2B (possible human carcinogen); EPA Group B2 [1]. Its historical importance to cancer research far exceeds any current exposure concern [2].

Research laboratory workers in carcinogenesis, metabolism, and DNA repair studies [1].

1. Handle in certified fume hood with double nitrile gloves and lab coat [1]. 2. Institutional biosafety committee review and hazardous chemical storage required [2]. 3. Deactivate waste by oxidation before disposal [1].